Effect of COVID-19 Pandemic on Pediatric Cancer Care

August 10, 2020 updated by: Mahmoud Motaz Elzembely, South Egypt Cancer Institute
Observational cohort study to assess the effects of COVID19 on pediatric cancer care in Egypt and the Arab World through a survey applied to pediatric oncologists who will be interviewed either directly or through the internet to assess the effect of COVID 19 on pediatric cancer care

Study Overview

Status

Unknown

Conditions

Detailed Description

Corona viruses are single stranded enveloped RNA viruses with helical capsids. They infect wide variety of hosts including humans and animals. Coronavirus disease 2019 (COVID-19) was first described in December 2019 in Wuhan, the capital of China's Hubei province. A novel corona virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the causative organism. On 30 Jan 2020, WHO declared COVID-19 as a Public Health Emergency of International Concern (PHEIC). Subsequently on 11 March 2020, WHO declared COVID-19 as a pandemic. On April 30, 2020; 3,239,220 confirmed cases were diagnosed across the globe with 228,860 deaths. The united states has the highest number of cases followed by spain and Italy. The first confirmed case of COVID-19 in Egypt was reported on 14 February 2020. As of April 30, 2020, there have been 5,537 confirmed cases, 1381 recovered and 392 deaths The overall global incidence of cancers in children aged 0-14 years is 140·6 per million, whereas, It's 130.9 per million in Egypt. Although cancer is a rare disease among children and adolescent, It's one of the leading causes of death. The prognosis of childhood cancer has significantly improved over the past decades with 5-year survival rates improved from 58% in the mid-1970 to around 83% in 2008-2014.

Little is known about the effects of COVID-19 on children with cancer. Children with cancer face numerous challenges during COVID-19 pandemic. Children with cancer are immunocompromised because of cancer or anti-cancer therapy. They have to be hospitalized to receive their anti-cancer therapy. The major problem we-as pediatric oncologist- face nowadays is how to organize pediatric cancer care in the COVID-19 ERA.

Study Type

Observational

Enrollment (Anticipated)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Assiut, Egypt, 71515
        • Recruiting
        • South Egypt Cancer Institute, Assiut University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Pediatric oncologists working in cancer centers in Egypt and the Arab world will be interviewed either directly or through the internet to assess the effect of COVID 19 on pediatric cancer care

Description

Inclusion Criteria:

  • Pediatric oncologists working in cancer centers in Egypt and the Arab world during COVID 19 pandemic

Exclusion Criteria:

  • Pediatric oncologists not caring for patients during COVID 19 pandemic

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
pediatric cancer care pattern during COVID 19 pandemic
Time Frame: 3 months
Patterns of data will be mined to understand pediatric cancer care adaptation during COVID 19 pandemic
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 15, 2020

Primary Completion (Actual)

August 1, 2020

Study Completion (Anticipated)

September 1, 2021

Study Registration Dates

First Submitted

May 1, 2020

First Submitted That Met QC Criteria

May 1, 2020

First Posted (Actual)

May 5, 2020

Study Record Updates

Last Update Posted (Actual)

August 12, 2020

Last Update Submitted That Met QC Criteria

August 10, 2020

Last Verified

August 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

3
Subscribe